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Background: The distinguishing of intrapulmonary metastatic tumors from multiple primary lung cancers is difficult
but of great importance for the therapeutic management and prognosis of these patients.
Methods: We used genomic DNA analyzed by six microsatellites (D7S1824, D15S822, D2S1363, D10S1239, D6S1056,
and D22S689) with PCR to identify discordant allelic variation from 12 patients. There are five patients with multiple
primary lung cancers and seven patients who were diagnosed with intrapulmonary metastases from 850 patients
with primary lung cancer in our hospital. The experiments were approved by the West China Hospital Ethics
committee (No. 2013 (33)) and all patients agreed to participate in the study and signed an informed consent form.
Results: In the group of metachronous lung tumor, three of five patients have different histological types and one
of five patients have the same histological type which showed “contradictory trend”. The other one showed
“unique trend”. In the second group (intrapulmonary metastasis lung tumor), one patient showed “contradictory
trend” and the others showed “unique trend”.
Conclusions: “Different trends” are useful in discrimination of intrapulmonary metastasis lung cancer and multiple
primary lung cancer even diagnosed with the histopathological evaluation.
Keywords: Primary metachronous lung cancer, Metastatic lung cancer, Microsatellite analysisBackground
It is known that patients with pulmonary neoplasms are
at an increased risk for a second tumor in the lung, ei-
ther at the same time or later in their life [1-3]. Dual pri-
mary lung cancer refers to two or more primary cancers
in different sites of one or both lungs, with either con-
sistent or different histology but no association between
two cancers. Based on the time when the tumors are
identified, the disease can be classified as synchronous
or metachronous [4]. The incidence of multiple primary
lung cancers has been reported to range from 0.7% to
15% of patients with lung cancer [5-9]. The frequency of
recorded synchronous or metachronous lung cancers
has been increasing in the recent years because of the
development of early detection techniques, such as
computed tomography (CT) and positron emission* Correspondence: cheguowei_hx@aliyun.com
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unless otherwise stated.tomography (PET), and advances in cancer therapy. Al-
though surgical treatment can also be a curative option
for multiple primary lung cancers as well as single lung
cancer, the 5-year survival of patients with synchronous
multiple primary lung cancers has been reported to
range from 0% to 44% [10,11] despite an early diagnosis.
One of the reasons for such a wide range in this survival
data is that patients who were clinically diagnosed with
multiple primary lung cancers may include some pa-
tients with intrapulmonary metastasis. At present, the
majority of multiple primary lung cancers are misdiag-
nosed as metastatic cancer in the issue based on path-
ology and radiology. Especially, when patients develop
multiple, morphologically similar lung cancer, the clin-
ical diagnosis becomes critical for the selection of an ap-
propriate treatment. In the absence of carcinoma in situ,
the morphologic similarity between the first and the sec-
ond lung neoplasm can make it impossible to make the
diagnostic distinction between metachronous primary
neoplasms and solitary pulmonary metastasis. Thus,his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the aerodigestive tract cannot definitively distinguish
multiple primary cancers from metastatic disease when
solitary, histologically similar cancers arise synchron-
ously or metachronously in an individual patient.
Recent advances in molecular biology have provided
several markers that can be used for clonal analysis
[12-14]. Allelic variation between neoplasms often re-
flects accumulation of differential chromosomal deletion
events [15]. In our previous study, we analyzed genomic
instability expression profiles in 18 patients, whose his-
tologies indicated that they were primary synchronous
lung cancers, with ten cases of pulmonary tumors with
metastasis (to the brain, sternum, or adrenal gland) se-
lected for comparison. We found that, with polymorphic
microsatellite markers, the “unique trend” that repre-
sents metastasis cancers and the “contradictory trend”
that represents primary multiple tumors are useful in
the diagnosis of synchronous multiple lung tumors [16].
In this study, we used a PCR-based approach to screen
polymorphic microsatellite markers as a discrimination
marker of double primary lung cancers from intrapul-
monary metastasis. We examined five patients with
metachronous multiple lung tumors and seven patients
diagnosed with intrapulmonary metastasis for their vari-
ations in allele numbers. The results support the mech-
anism of “different trends” and illustrate the potential
power of molecular techniques in differential diagnosis.Methods
Patients and clinical features
All the patients had undergone a surgical resection
between April 2003 and December 2013 in the Depart-
ment of Thoracic Surgery at West China Hospital,
Sichuan, China. Five patients were diagnosed with mul-
tiple primary lung cancers according to criteria proposed
by Martini and Melamed [17], and seven patients were
diagnosed as intrapulmonary metastasis. The five pa-
tients were classified as metachronous tumors with or
without the same histological type. Among them, two
patients were diagnosed as having multiple primary
lung cancers with the same histological types, and three
patients were diagnosed as having different histological
types. All patients were followed up and their status
recorded as alive or dead. The first tumor was desig-
nated as tumor 1 (T1), while subsequent tumors were
designated as tumor 2 (T2). The age, site of tumor,
histology, sex, and the status of following up for each
patient are given in Table 1 and Figures 1 and 2. The
experiments were approved by the West China Hospital
Ethics Committee (No.2013 (33)), and all patients
agreed to participate in the study and signed an in-
formed consent form.Preparation of genomic DNA
Sections stained with hematoxylin and eosin (H & E)
were used to identify regions of well-preserved tumor
tissue containing ≥90% tumor. Tumor tissues from three
to five unstained 6-μm sections were dissected free of
tumor stroma using a sterile scalpel for each case and
collected in 600 μl of xylene. Deparaffinization was
achieved by incubating for 5 min in xylene, followed by
centrifugation at 13,000× g for 4 min to collect deparaf-
finized tissues. The tissue pellet was resuspended in
600 μl of 95% ethanol, washed for 6 min, and centri-
fuged at 13,000× g for 5 min. The resulting tissue pellet
was dried, and DNA was isolated using a paraffin-
embedded tissue genomic DNA extraction kit (Bioteke
Corporation, Beijing, China) according to the manufac-
turer’s protocol.
Microsatellite PCR analysis
Genomic DNA collected from tumor samples were
examined for six polymorphic microsatellite markers
including: D10S1239, D7S1824, D2S1363, D6S1056,
D15S822, and D22S689. The oligonucleotide primers
corresponding to each microsatellite marker were pur-
chased from Sangon Biotech (Shanghai, China) Co., Ltd.
For PCR, the reaction samples were each prepared to a
total volume of 25 μL as follows: 1 μL each primer, 1 μL
template DNA, 9.5 μL nuclease-free water, and 12.5 μL
PCR Mix (2X). Amplifications were carried out in a
Perkin Elmer Thermocycler (Perkin Elmer, Waltham,
USA) using a step-cycle program consisting of 39 cycles
of 95°C for denaturing (30 s), 55°C for annealing (30 s),
and 72°C for extension (1 min). PCR products were
fractionated on 6% polyacrylamide gels containing Tris-
borate/EDTA (pH 8.0) and visualized by ethidium brom-
ide staining.
Results
Analysis of metachronous lung tumor with same
histological types
Two cases presented with metachronous multiple tu-
mors of the lung were studied for molecular analysis.
The microsatellite PCR results for each of these patients
are given in Table 1.
Patient 1 was diagnosed with adenocarcinoma of the
right lower lobe at the first time. Twenty-nine months
later, a newly node was found in the right upper lobe. In
this case, the molecular evidence was based upon dis-
concordant results with D2S1363. Allele corresponding
to microsatellite marker D2S1363 was observed in T1
but was not detected in T2.
Molecular analysis of patient 2 provided a clear ex-
ample of a patient as having metachronous lung tumor.
Alleles for D2S1363 and D7S1824 were detected in the
T1 that were not observed in the subsequent lung tumor
Table 1 Clinical, pathologic data and microsatellite marker of all patients




Follow-up D2S1363 D6S1056 D7S1824 D10S1239 D15S822 D22S689
G1 P1 T1 41 F RLL AC 29 Alive +++ ++ + + - -
T2 RUL AC - ++ + + - -
P2 T1 71 M RUL AC 42 Dead + - + - - -
T2 RML AC - - - + - -
G2 P3 T1 72 M RLL SCC 40 Dead ++ - + + - -
T2 LUL AC - + + - - -
P4 T1 63 M RML AC 12 Alive - + + ++ + -
T2 RUL SCC + + + - - -
P5 T1 60 M LUL SCC 17 Alive - - + - - +
T2 RLL AC + ++ - + - +
P6 T1 62 M LLL SCC None Alive + - + + ++ +
G3 T2 LUL SCC + - + + - -
P7 T1 65 M LUL AC None Alive - - + ++ - +
T2 LLL AC - - - ++ - -
P8 T1 55 F RUL AC None Alive + + + - - +
T2 RML AC - - + - - -
P9 T1 66 M RUL AC None Dead - - + + - -
T2 RLL AC + ++ + + + -
P10 T1 51 F RUL AC None Alive ++ ++ + + + +
T2 RLL AC ++ + + - + +
P11 T1 40 F RUL AC None Alive + - + +++ - -
T2 LLL AC + + + ++ ++ +
P12 T1 56 M LUL SCC None Alive + + + + - -
T2 LLL SCC + - + - - -
T1 refers to the first neoplasm; T2 refers to the second neoplasm.
G1, metachronous lung tumor with same histological types; G2, metachronous lung tumor with different histological types; G3, intrapulmonary metastasis lung
tumors; AC, adenocarcinoma; SCC, squamous carcinoma; RUL, right upper lobe; RML, right middle lobe; RLL, right lower lobe; LUL, left upper lobe; LLL, left
lower lobe.
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detected in the lung cancer (T2) that was not observed
in the T1.
Analysis of metachronous lung tumor with different
histological types
Three cases of metachronous tumors with different
histological types (Table 1) of the lung were also studied
for molecular analysis. In the typical case of patient 5,
the first neoplasm was found in the left upper lobe,
which was pathologically diagnosed as squamous cell
carcinoma after a successful surgical lobectomy. Seven-
teen months later, newly ground-glass opacity was ob-
served in the right lower lobe by CT (Figure 2). Then,
the patient underwent a pulmonary wedge resection and
the pathology was adenocarcinoma (Figure 2). In our
study, the observed allelic variation of patient 5 at
D2S1363, D6S1056, and D10S1239 suggests that T1
could be derived from T2, consistent with dual primarytumors (Figure 2 and Table 1). However, the allelic vari-
ation noted at D7S1824 contradicts this possible lineage
relationship.
In the other two patients, alleles corresponding to
microsatellite markers D2S1363 and D10S1239 were
amplified in DNA from T1 of patient 3 but were not ob-
served in DNA from T2. However, in the same patient,
D6S1056 was detected in DNA from T2 but was not
found in DNA from T1. Similar results were obtained
for patient 4.
Analysis of intrapulmonary metastasis lung tumor
Seven pairs of tumors were chosen, each consisting of a
“primary lung tumor” and a “metastatic tumor” (Table 1).
Lineage relationships for each of these tumor pairs were
determined by molecular analysis.
For example, alleles corresponding to microsatellite
markers D2S1363, D6S10556, and D22S689 were de-
tected in DNA from T1 of patient 8 whose provided a
Figure 1 CT features, histological features, and molecular
analysis of patient 8 in the intrapulmonary metastasis group.
A and B: the first tumor and the second tumor of patient 8. C and
D: two tumors of patient 8 in the intrapulmonary metastasis group
were diagnosed pathologically as adenocarcinoma (H & E staining
X100). E: T1 refers to the tumor in the right upper lobe, and T2
refers to the tumor in the right middle lobe.
Figure 2 CT features, histological features, and molecular
analysis of patient 5 in metachronous lung tumor group. CT
features, histological features, and molecular analysis of patient 5 in
the metachronous lung tumor group of different histological types.
A and B: the first tumor and the second tumor of patient 3 in the
metachronous lung tumor group of different histological types.
C and D: the first tumor and the second tumor were diagnosed
respectively as squamous carcinoma and adenocarcinoma (H & E
staining X100). E: T1 refers to the first tumor in the left upper lobe,
and T2 refers to the second tumor in the right lower lobe.
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plasms but were not observed in DNA from T2 (Figure 1
and Table 1). Likewise, alleles corresponding to micro-
satellite markers D7S1824 and D22S689 were observed
in T1 of patient 7 but were not detected in T2. Similar
results were obtained for patients 6, 10, and 12. In the
case of patient 9, which the tumor designations were
assigned arbitrarily when multiple tumors were surgi-
cally removed from a given patient at the same time,
represented inverted consequence in the Table 1. Alleles
for D2S1363, D6S1056, and D15S822 were observed in
T2 but were not detected in T1.
In the case of patient 11 (Figure 3 and Table 1), the
two neoplasms were found in the left lower lobe and
right upper lobe at the same time by CT. She was a
non-smoker and had no exposure to any environmental
fumes or dust. Physical examination revealed normal
breath sounds in both of the lung fields. Laboratory
findings were within normal limits. Her pulmonary func-
tion tests and cardiovascular examination revealed nor-
mal performance. According to the fundamental state of
all the examinations, the patient underwent a successful
left lower lobectomy and right upper pulmonary wedge
resection at the same time. The pathology of two tumorswas adenocarcinoma. The patient was followed up with-
out evidence of recurrence to date. In our study, the two
tumors share common allelic patterns for two microsat-
ellite marker at D2S1363 and D7S1824 but show differ-
ing allelic patterns for four microsatellite markers at
D6S1056, D10S1239, D15S822, and D22S689 (Figure 3
and Table 1). Alleles corresponding to microsatellite
markers D10S1239 were observed in T1 but were not
detected in T2. At the same time, microsatellite markers
D6S1056, D15S822, and D22S689 were observed in T2
but were not detected in T1.
Discussion
It may be easy to diagnose multicentric primary lung can-
cers in multiple lung lesions when their histological types
are different. However, if they show the same histological
type, it is often difficult to discriminate multiple primary
lung cancers from intrapulmonary metastasis.
The differential diagnosis of intrapulmonary metastatic
lung cancer (via bloodstream dissemination) verse pri-
mary lung cancer is also perplexing in clinical setting;
however, tumors with consistent histology and N2 and
Figure 3 CT features, histological features, and molecular
analysis of patient 11 in the intrapulmonary metastasis group.
A and B: the first tumor and the second tumor of patient 11. C and D:
two neoplasms in different chest of patient 11 in the intrapulmonary
metastasis group were diagnosed pathologically as adenocarcinoma
(H & E staining X100). E: T1 refers to the tumor in the right upper lobe,
and T2 refers to the tumor in the left lower lobe.
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diagnosed as intrapulmonary metastasis [4].
On the basis of the analyses of the overall survival
among pathologically staged cases, nodules within the
same lobe as the primary lesion are categorized by the
International Union Against Cancer (UICC) as T4 and
those located in the different lobe (whether it is ipsilat-
eral or contralateral side) as M1. The International As-
sociation for the Study of Lung Cancer (IASLC) lung
cancer-staging project recommended changes in the T
classification to subclassify additional nodules in the
same lobe as T3, nodules in the ipsilateral different lobe
as T4, and those in a contralateral lobe as M1 [18]. Their
different biologic behaviors may, thus, be responsible
for prognostic differences. Because some of the patients
with intrapulmonary metastasis show poor prognosis, it
is necessary to discriminate intrapulmonary metastasis
from multiple primary lung cancers by exploring new
practical techniques and markers.
The pathogenic mechanism of multiple primary lung
cancer is still unclear, but several authors have reported
the feasibility of clonal analyses between tumors to dis-
criminate multiple primary lung cancers from intrapul-
monary metastasis. A multiple-gene analysis to identifythe clonality in a combination of multiple-gene muta-
tions, such as a p53 gene mutation, K-ras mutation, and/
or loss of heterozygosity, has been reported [19-24].
Mitsudomi analyzed the p53 gene mutation in 16 pa-
tients with multiple primary lung cancers [25]. Among
those patients, seven were not informative because of
the absence of the p53 mutation in both tumors. Among
nine patients who had at least one p53 mutation in their
pair of tumors, six were suggested to be of different
clonal origin and were diagnosed with multiple primary
lung cancers. Matsuzoe reported that 7 of 20 patients
who were clinically diagnosed to have intrapulmonary
metastasis showed different p53 gene mutations between
the two lesions, thus indicating these lesions to be mul-
tiple primary lung cancers [26]. These reports indicate
that the somatic mutations of the p53 gene may be a
suitable biological factor to identify multiple primary
lung cancers. Although there is a positive expression of
the p53 due to a prolonged half-life time induced by a
somatic mutation of the p53 gene, the concordance rate
between p53 gene mutations and immunopositivity in
NSCLC is reported to be 60% to 70% [27,28]. According
to Ono’s study, the sum value of the differences in the
expression ratio of four proteins (p53, p16, p27, and c-
erbB2) was evaluated in immunohistochemically stained
specimens among multiple primary lung cancers and
intrapulmonary metastasis [29]. Yoshimoto reported a
case, diagnosed as double primaries, that is distinguished
by EGFR gene mutation analysis [30].
Mercer et al. [15] found that detections of microsatel-
lite alterations and deletion sites in tumor cell DNA
could be used as diagnostic and prognostic markers for
multiple cancers. In our previous study [16], the results
demonstrated that molecular analysis of allelic variations
at polymorphic microsatellite markers can be used to de-
termine lineage relationships between multiple tumors, fa-
cilitating the discrimination of second primary cancer
versus metastatic disease. With polymorphic microsatellite
markers, the “unique trend” that represents metastasis
cancers and the “contradictory trend” that represents pri-
mary multiple tumors are useful in the diagnosis between
tumors found at the same time in the pulmonary even di-
agnosed with the histopathological evaluation.
In the first group, as the consequences showed of two
patients in our study, alleles in patient 2 corresponding
to microsatellite markers D2S1363 and D7S1824 were in
the DNA from the first tumor but were reduced or not
observed in the DNA from the second. In contrast, allele
corresponding to D10S1239 was detected in the lung
cancer (T2) that was not observed in the T1. Molecular
analysis of these tumors identified discordant allelic vari-
ations involving three different microsatellite markers,
arguing that these cancers arose independently. These
mutually exclusive allelic losses strongly suggest that
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cancer in this patient represents a second primary car-
cinoma rather than a solitary metastatic lesion derived
from the other one. The characteristic of this “contra-
dictory trend” is representative as our study before.
However, in the case of patient 1, the two tumors share
common allelic patterns for five microsatellite markers
but show differing allelic patterns for only one microsat-
ellite marker at D2S1363. The allele corresponding to
the microsatellite marker D2S1363 was observed in T1
but was not detected in T2. The results strongly suggest
that the T1 has given rise to T2 and suggest that the T1
metastasized to the T2. Given the histopathology for
these neoplasms, a conclusion that a metastatic lesion
derived from the other one was the same as ours. The
“unique trend” is made with less confidence when the
numbers of discordant changes are this few. Given that
there is a concern about the effects of intra-tumor het-
erogeneity on this type of analysis, increased numbers of
microsatellite markers (and observations of allelic vari-
ation) might be required to draw clear conclusions.
The next groups of tumors we studied were metachro-
nous tumors with different histological types of the lung,
and the result showed a “contradictory trend”. The paired
tumors in case 3 appeared to be typical of the three pa-
tients. The observed allelic variation at D7S1824 suggests
that T2 could be derived from T1, consistent with meta-
static disease. However, the allelic variations of D2S1363,
D6S1056, and D10S1239 were noted in T2 but not ob-
served in T1; which means that T1 could be also derived
from T2, so that the result contradicts the possible lineage
relationship of metastatic disease.
Among the third group including seven intrapulmon-
ary metastasis lung tumors diagnosed by pathology, the
results of cases 6, 7, 8, 9, 10, and 12 present typical
“unique trend” and it suggests that all the patients repre-
sent the real intrapulmonary metastasis lung tumors.
However, the controversial consequences happened in
patient 11. As the result showed before, patient 6 pro-
vided a clear example of a patient with two unrelated tu-
mors, where the consequence suggests a “contradictory
trend”. In this case, microsatellite markers D6S1056,
D15S822, and D22S689 were observed in T2 but were
not detected in T1. At the same time, alleles correspond-
ing to microsatellite marker D10S1239 was observed in
T1 but was not detected in T2.
Conclusion
It is important to discriminate intrapulmonary metastasis
from multiple primary lung cancers. However, in some
cases, such discrimination can be difficult. Although new
methods have recently been applied to this differentiation,
they are not practical at present. The results of this study
suggest that not only immunohistochemical analyses ofdifferential protein expression profiles of multiple genes
can be used but also molecular analysis of allelic variations
at polymorphic microsatellite markers to distinguish mul-
tiple primary lung cancers from intrapulmonary metasta-
sis. The “unique trend” that represents metastasis cancers
and the “contradictory trend” that represents primary mul-
tiple tumors are useful in the diagnosis between tumors
even diagnosed with the histopathological evaluation.
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